The Cigna Group
CI
$304.50
+3.76%
The Cigna Group is a global health services company that provides pharmacy benefit management (PBM) through its Evernorth segment and health insurance through its Cigna Healthcare segment. As one of the largest PBMs in the U.S., Cigna holds a strong competitive position, particularly after its 2018 merger with Express Scripts, and serves a diverse client base including employers, government entities, and health plans. The current investor narrative centers on Cigna's strategic pivot, including its exit from the individual exchange market and a strategic review of eviCore, while it raised its 2026 outlook after a strong quarterly performance, balancing growth initiatives with execution risk.…
CI
The Cigna Group
$304.50
Related headlines
Investment Opinion: Should I buy CI Today?
Rating: Buy. Cigna offers a compelling value proposition with a forward P/E of 8.76x, a 41.6% discount to the industry average, and a consensus analyst target implying 38.2% upside. The core thesis is that the market is overly pessimistic about margin pressures and strategic risks, while the company's strong free cash flow and revenue growth provide a margin of safety.
Supporting evidence includes: (1) forward P/E of 8.76x vs. industry 15x; (2) TTM revenue growth of 10.39% with analyst estimates of 22.2% growth next year; (3) TTM free cash flow of $8.39 billion supporting buybacks and dividends; (4) ROE of 14.28% indicating efficient capital use. The implied analyst target of ~$405.70 offers significant upside, and the low beta of 0.30 reduces downside risk.
Risks to the thesis include margin compression (gross margin down to 7.66%), execution risk from strategic pivots, and potential regulatory headwinds. This Buy rating would be downgraded to Hold if forward P/E expands above 12x without margin improvement, or if revenue growth decelerates below 8%. The stock appears undervalued relative to its history and peers, with the trailing P/E near the lower end of its 5-year range.
Sign up to view all
CI 12-Month Price Forecast
Cigna's valuation is deeply discounted relative to peers and its own history, presenting a compelling risk/reward. The low beta and strong free cash flow provide downside protection, while the potential for margin stabilization and revenue growth offers upside. However, margin compression and execution risk from strategic pivots warrant caution. The bullish stance is supported by the valuation gap and analyst sentiment, but confidence is medium due to the uncertainty around margin trends. An upgrade to high confidence would require evidence of margin expansion in upcoming quarters, while a downgrade would follow sustained margin deterioration or revenue deceleration below 8%.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on The Cigna Group's 12-month outlook, with a consensus price target around $395.85 and implied upside of +30.0% versus the current price.
Average Target
$395.85
5 analysts
Implied Upside
+30.0%
vs. current price
Analyst Count
5
covering this stock
Price Range
$244 - $396
Analyst target range
Cigna is covered by 5 analysts, with a consensus leaning bullish. The average EPS estimate for the next fiscal year is $46.32, with a low of $44.86 and a high of $47.73. The average revenue estimate is $335.88 billion, implying 22.2% growth from the trailing twelve months. The consensus recommendation is Buy, with recent upgrades from Bernstein (to Outperform) and reaffirmations from Piper Sandler (Overweight), Truist (Buy), and others. The average target price is not explicitly provided, but based on the forward P/E of 8.76x and average EPS estimate of $46.32, the implied target is approximately $405.70, representing 38.2% upside from the current price of $293.46. The target range spans from a low of $44.86 EPS (implying ~$393 at 8.76x P/E) to a high of $47.73 EPS (implying ~$418), suggesting a relatively tight spread of about 6.4%, indicating strong conviction among analysts. The high target assumes successful margin expansion and revenue growth from the Evernorth segment, while the low target may reflect risks from the individual exchange exit and potential regulatory headwinds. Recent ratings actions have been uniformly positive, with no downgrades in the past six months, reinforcing the bullish sentiment.
Bulls vs Bears: CI Investment Factors
Cigna presents a compelling value opportunity with a forward P/E of 8.76x, a 41.6% discount to the industry average, and strong free cash flow of $8.39 billion supporting capital returns. However, margin compression (gross margin down to 7.66%) and revenue deceleration (10.39% YoY growth) raise concerns about near-term profitability. The bull case is supported by analyst consensus Buy rating and 38.2% upside to the implied target, while the bear case hinges on execution risk from strategic pivots and persistent underperformance. The single most important tension is whether Cigna can stabilize and expand margins while maintaining revenue growth; if margins improve, the stock could re-rate significantly, but if they continue to compress, the valuation discount may persist or widen.
Bullish
- Compelling forward P/E discount: Cigna trades at a forward P/E of 8.76x, a 41.6% discount to the healthcare plans industry average of 15x. This deep discount implies the market is not fully pricing in expected earnings growth of ~41% over the next year, offering significant upside if the company executes.
- Strong free cash flow generation: TTM free cash flow stands at $8.39 billion, providing ample capacity for share repurchases and dividends. The dividend yield of 2.2% and a payout ratio of 27% leave room for further capital returns, supporting shareholder value.
- Robust revenue growth trajectory: Q4 2025 revenue grew 10.39% YoY to $72.47 billion, driven by the Evernorth PBM segment ($64.74 billion). The average analyst revenue estimate for next fiscal year is $335.88 billion, implying 22.2% growth from TTM, indicating sustained momentum.
- Analyst consensus bullish with upside: The consensus rating is Buy, with an implied average target of ~$405.70 based on forward P/E and EPS estimates, representing 38.2% upside from the current price of $293.46. Recent upgrades from Bernstein and reaffirmations from Piper Sandler and Truist reinforce positive sentiment.
Bearish
- Margins under pressure from PBM mix: Gross margin compressed to 7.66% in Q4 2025 from 8.52% in Q3 2025, and net margin fell to 1.70% from 2.68%. The shift toward lower-margin PBM services and higher medical costs is eroding profitability, which could limit earnings growth.
- Revenue growth deceleration trend: YoY revenue growth decelerated from 11.7% in Q2 2025 to 10.39% in Q4 2025. While still robust, the deceleration suggests a maturing PBM business and potential headwinds from the exit of the individual exchange market.
- Strategic pivot introduces execution risk: Cigna's exit from the individual exchange market and strategic review of eviCore create near-term uncertainty. These moves, while potentially beneficial long-term, could distract management and lead to revenue or cost disruptions during the transition.
- High short ratio signals bearish sentiment: The short ratio of 4.73 days to cover indicates elevated short interest relative to average volume. This suggests a significant portion of the market is betting against the stock, potentially reflecting concerns about margin compression or regulatory risks.
CI Technical Analysis
Cigna's stock is in a recovery phase, trading at $293.46 as of July 10, 2026, which is 93.0% of its 52-week range ($239.51–$315.47). The 1-year price change is -4.96%, indicating a mild downtrend over the long term, but the stock has rebounded from its 52-week low of $239.51, suggesting a potential bottoming pattern. The current price sits near the midpoint of the range, reflecting a neutral stance after a volatile period. Short-term momentum is mixed: the 1-month change is -0.79%, while the 3-month change is +8.19%, showing a deceleration in the most recent month. This divergence from the 1-year downtrend could signal a short-term pullback within a broader recovery, as the stock failed to sustain its April–May rally. The 6-month change of +5.20% confirms a gradual upward bias, but the recent loss of momentum warrants caution. Key support lies at the 52-week low of $239.51, a break below which would signal a resumption of the downtrend and potential further downside. Resistance is at the 52-week high of $315.47; a breakout above this level would indicate strong bullish momentum and a potential trend reversal. Cigna's beta of 0.30 is significantly lower than the market, implying the stock is 70% less volatile than the S&P 500, which may appeal to risk-averse investors but also limits upside participation in market rallies.
Beta
0.30
0.30x market volatility
Max Drawdown
-26.9%
Largest decline past year
52-Week Range
$240-$315
Price range past year
Annual Return
+0.4%
Cumulative gain past year
| Period | CI Return | S&P 500 |
|---|---|---|
| 1m | +2.2% | +1.0% |
| 3m | +11.7% | +7.9% |
| 6m | +12.4% | +8.5% |
| 1y | +0.4% | +20.1% |
| ytd | +9.1% | +9.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
CI Fundamental Analysis
Cigna's revenue trajectory is robust, with Q4 2025 revenue of $72.47 billion, up 10.39% year-over-year from $65.65 billion in Q4 2024. The trailing twelve-month revenue reached $274.96 billion, driven by strong growth in the Evernorth segment ($64.74 billion in Q4 2025) and Cigna Healthcare ($12.51 billion). However, revenue growth has decelerated from the 11.7% YoY growth seen in Q2 2025, indicating a slight moderation. The company's profitability is solid, with net income of $1.23 billion in Q4 2025 and a net margin of 1.70%, though this is down from 2.68% in Q3 2025. Gross margin compressed to 7.66% in Q4 2025 from 8.52% in Q3 2025, reflecting higher medical costs or mix shift toward lower-margin PBM services. Operating margin of 2.96% is stable but below the 3.70% in Q3 2025, suggesting some margin pressure. Cigna maintains a healthy balance sheet with a debt-to-equity ratio of 0.75 and a current ratio of 0.85, indicating adequate liquidity. Free cash flow for Q4 2025 was $5.83 billion, bringing TTM free cash flow to $8.39 billion, which provides ample capacity for share repurchases and dividends. ROE of 14.28% is strong, reflecting efficient capital use, though the payout ratio of 27.04% leaves room for reinvestment.
Quarterly Revenue
$72.5B
2025-12
Revenue YoY Growth
+10.4%
YoY Comparison
Gross Margin
7.7%
Latest Quarter
Free Cash Flow
$8.4B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is CI Overvalued?
Since Cigna has positive net income, the primary valuation metric is the P/E ratio. The trailing P/E is 12.34x, while the forward P/E is 8.76x, implying the market expects earnings growth of roughly 41% over the next year. This gap suggests that the market is pricing in a significant earnings recovery, likely driven by cost savings and margin expansion. Compared to the healthcare plans industry average P/E of approximately 15x (based on sector data), Cigna's trailing P/E of 12.34x represents a 17.7% discount, which may be justified by its lower net margin (1.70% vs. industry average of ~3-4%) and recent margin compression. However, the forward P/E of 8.76x is a steep 41.6% discount to the industry forward average of 15x, indicating that the market is not fully pricing in the expected earnings growth. Historically, Cigna's trailing P/E has ranged from 7.6x (Q3 2022) to 32.6x (Q3 2024), with the current 12.34x near the lower end of its 5-year band. This suggests the stock is undervalued relative to its own history, potentially offering a value opportunity if the company can execute on its strategic initiatives and improve margins.
PE
12.3x
Latest Quarter
vs. Historical
High-End
5-Year PE Range -94x~33x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
8.4x
Enterprise Value Multiple
Investment Risk Disclosure
Financial & Operational Risks: Cigna's debt-to-equity ratio of 0.75 is manageable, but the current ratio of 0.85 indicates potential liquidity tightness. More concerning is the margin compression: gross margin fell from 8.52% in Q3 2025 to 7.66% in Q4 2025, and net margin dropped from 2.68% to 1.70%. This pressure stems from a mix shift toward lower-margin PBM services and rising medical costs. If margins continue to erode, earnings growth may disappoint relative to the 41% growth implied by the forward P/E gap. Free cash flow of $8.39 billion provides a buffer, but sustained margin decline could impair the company's ability to invest and return capital.
Market & Competitive Risks: Cigna's trailing P/E of 12.34x is a 17.7% discount to the industry average of 15x, but the stock has underperformed the S&P 500 by 25.59% over the past year. The low beta of 0.30 limits downside but also caps upside in market rallies. Competitive threats include other large PBMs like CVS Caremark and OptumRx, which could pressure pricing. Regulatory risks, such as potential PBM reform or drug pricing legislation, could disrupt Cigna's business model. The recent news of exiting the individual exchange market and reviewing eviCore adds uncertainty, though it may streamline operations.
Worst-Case Scenario: In a severe downturn, Cigna could face a perfect storm of margin compression, revenue deceleration from PBM contract losses, and regulatory headwinds. The 52-week low of $239.51 represents a potential 18.4% decline from the current price of $293.46. If the company fails to execute its strategic pivot and margins continue to fall, the stock could revisit that low or even break below it, leading to a loss of up to 18-25% for investors. The historical max drawdown of -26.91% suggests that in extreme scenarios, losses could approach that level, implying a potential decline to around $214.
FAQ
The primary risks are: (1) Margin compression—gross margin fell to 7.66% in Q4 2025 from 8.52% in Q3, and net margin dropped to 1.70%, which could continue to pressure earnings. (2) Execution risk from the strategic pivot, including the exit from individual exchanges and eviCore review, which may cause near-term disruptions. (3) Regulatory risk—potential PBM reform or drug pricing legislation could impact Cigna's core business. (4) Competitive pressure from other large PBMs like CVS Caremark and OptumRx, which could lead to contract losses or pricing concessions. The most severe risk is a combination of margin erosion and revenue deceleration, which could drive the stock back to its 52-week low of $239.51.
The 12-month outlook is cautiously bullish. The base case (50% probability) sees the stock trading between $340 and $380, driven by steady revenue growth and modest margin recovery, aligning with the analyst average target of ~$405.70. The bull case (30% probability) targets $380-$420, assuming margin improvement and new contract wins. The bear case (20% probability) sees the stock falling to $240-$290 if margins continue to compress or a major contract is lost. The most likely scenario is the base case, with the stock gradually appreciating as the market gains confidence in Cigna's strategic direction. Key assumptions include revenue growth of 10-12% and gross margin stabilizing around 8%.
Cigna appears undervalued based on both absolute and relative metrics. The trailing P/E of 12.34x is a 17.7% discount to the industry average of 15x, and the forward P/E of 8.76x is a 41.6% discount. Historically, the stock's trailing P/E has ranged from 7.6x to 32.6x over the past 5 years, and the current level is near the lower end, suggesting it is cheap relative to its own history. The PEG ratio of 0.15x further indicates undervaluation relative to expected earnings growth. The market appears to be pricing in significant margin and execution risks, which may be overdone given the company's strong cash flow and revenue growth.
Cigna presents a compelling risk/reward for value-oriented investors. The stock trades at a forward P/E of 8.76x, a 41.6% discount to the healthcare plans industry average of 15x, and analysts see 38.2% upside to the implied target of ~$405.70. The company generates strong free cash flow of $8.39 billion TTM, supporting a 2.2% dividend yield and share buybacks. However, margin compression (gross margin down to 7.66%) and execution risk from strategic pivots are key concerns. For investors with a 12-month horizon and tolerance for near-term volatility, CI is a good buy at current levels, but those seeking immediate momentum may prefer to wait for evidence of margin stabilization.
Cigna is better suited for long-term investment given its low beta of 0.30, which limits short-term trading opportunities, and its value-oriented profile. The stock's 1-year performance of -4.96% versus the S&P 500's +20.63% highlights its lack of momentum, making it less attractive for short-term traders. However, for long-term investors, the deep valuation discount, strong free cash flow, and dividend yield provide a margin of safety. A minimum holding period of 12-18 months is recommended to allow the strategic pivot to materialize and margins to stabilize. The stock could also serve as a defensive holding in a diversified portfolio due to its low correlation to the market.